DecisionRx, Inc.’s Post

30x. That's the cost of medication failure compared to the cost of drugs themselves. DecisionRx's Medication Optimization Platform eliminates this, directly addressing the $674 billion in unnecessary health care spending (16% of total costs) and 250,000 avoidable deaths in the U.S. each year. When we know better, we must do better. #medicationmanagement #precisionmedicine #pharmacogenomics #valuebasedcare

It is past time to put patients over profits. Action is needed NOW. The Forum supports efforts to reform PBMs, increase free market competition, and make lower-cost biosimilars accessible to patients. Read more in Forbes: https://lnkd.in/dCN9hG7h

Great article discussing the evolution of PBMs and the impact of mega-mergers and industry consolidation in healthcare. Understanding incentives by different stakeholders is crucial to promoting transparency, ultimately improving patients' access to affordable medicines and healthcare. #PBM #HealthcareIndustry #AccessToMedicines

This is all stuff we've been talking to Healthcare Purchaser Alliance members about for nearly a decade, but it's great to see the rest of the world catching on. There are so many opportunities for employers and patients to save when you move away from opaque, traditional PBM models. Transparency and value-based formularies exist with PBMs like Capital Rx (who will even share drug-specific rebate data), SmithRx, and others, and it's not uncommon to see 30% savings on total drug spend when making the move. With the Lewandowski v. J&J lawsuit alleging breach of fiduciary duty, moving away from traditional models is more important now than ever. Employers need real transparency to meet their fiduciary obligations!

As we navigate the evolving landscape, staying informed on the latest healthcare cost and affordability issues is crucial! KFF explores prescription drug pricing, site-neutral payments, and more. https://bit.ly/47WX1hH #Healthcare #HealthResearch #Poll

when you're focused on your employees and their families, and managing the total costs of healthcare across your entire organization, BeneCard PBF is the PBM that facilitates the best return for your employees, and your bottom line.

Insurers and employers are ditching the major PBM players. Tired of questionable practices, insurers and employers are switching from big-name PBMs to smaller, more transparent competitors. Why the switch? The major PBMs have been accused of tactics that inflate costs and steer patients towards expensive drugs. Additionally, smaller PBMs offer features like: - Passing on drug rebates directly - Openly negotiating drug costs - Higher reimbursements for pharmacies - Avoiding "spread pricing" (charging payers more than reimbursing pharmacies) Early results are promising: Health plans report significant cost savings and more control over pharmacy benefits with smaller PBMs. Learn more: https://hubs.ly/Q02GDTH70

The #InflationReductionAct is bringing changes to Medicare Part D, such as a new Medicare Prescription Payment Plan. These changes can create more affordable access for patients, and they also offer an opportunity for pharma to change affordability perceptions and improve product fulfillment. Here’s how companies can prepare. Thanks to our colleagues Ricky Yuen, Kyle Crowell and Sean Scobell who developed the thought piece. https://lnkd.in/dSYkDmti

In the ever-evolving landscape of healthcare, specialty drugs have emerged as both a blessing and a challenge. While these innovative medications offer hope for patients with complex and chronic conditions, their skyrocketing costs have become a significant concern for healthcare systems, insurers, and patients alike. As we navigate this complex terrain, it’s crucial to re-evaluate our approach to managing specialty drug costs without compromising patient care. https://lnkd.in/eqUMqnDm

The 4/5 Healthcare Labyrinth is live. Click below to read. Major stories: -- Mark Cuban saves on drugs -- Biosimilar change allowed by CMS -- MTM criteria changes -- Oscar Health's success -- Great 2025 Medicare Advantage rule summary #healthcare #healthcarereform #healthinsurance #healthcarelabyrinth